- Daiichi Sankyo, Inc. (Bernards, NJ)
- …effort. The Associate Director is also responsible for a broad array of brand functions including non-personal promotion, P&L management, budgeting, agency ... management, monthly and quarterly business reviews.Responsibilities- Develop and execute the consumer annual brand plan to ensure financial objectives are achieved. Evaluate competing strategies and tactics to advance the position of the assigned product… more
- Daiichi Sankyo, Inc. (Bernards, NJ)
- …of information; develops documents and materials for meetings and a wide array of audiences- Edits and produces advanced internal and external communications; acts ... on behalf of an executive for certain decisions or activities (eg, e-mails)- Create the QA Newsletter with Team- Administrative support includes but not limited to: Responsible for travel, Financial Administration as needed (eg tracking of expenses for travel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Piscataway, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Merck & Co. (Rahway, NJ)
- …development at our Company Research laboratories. TMB laboratories leverage a diverse array of technologies to develop biomarker assays to help confirm engagement of ... therapeutic targets and understand mechanisms of drug action and patient response. The Mass Spectrometry group within the TMB organization is seeking a highly motivated candidate to join our team. The individual will play a critical role in the development and… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Memphis, TN)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Novo Nordisk Inc. (Boulder, CO)
- …to identify and evaluate problems and determine appropriate solutions utilizing an array of analytical techniques Support regulatory filings as necessary Support the ... overall Chemical Development team goals with accurate budget and staff projections Maintain the highest level of scientific rigor and professionalism within our organization Physical Requirements 0-10% overnight travel required. Development of People Ensure… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
- Legend Biotech USA, Inc. (Raritan, NJ)
- …New Jersey, we are developing advanced cell therapies across a diverse array of technology platforms, including autologous and allogenic chimeric antigen receptor ... T-cell and natural killer (NK) cell-based immunotherapy.Legend Biotech entered into a global collaboration agreement with Janssen, one of the pharmaceutical companies of Johnson & Johnson, to jointly develop and commercialize ciltacabtagene autolecuel… more
